GLPwatch
Papers (9189)
Page 96 of 154, ranked by citation count.
- Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
- A Research Update on Exendin-4 as a Novel Molecule Against Parkinson's Disease.
- Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
- Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.
- Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.
- Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
- Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
- [Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].
- Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application.
- The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
- Molecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety.
- Semaglultide targets Spp1<sup>+</sup> microglia/macrophage to attenuate neuroinflammation following perioperative stroke.
- Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogs (exenatide) on cognitive function in hepatosteatosis.
- Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease.
- Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
- A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report.
- Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion.
- Liraglutide-related cholelithiasis.
- Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy.
- Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database.
- Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.
- Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.
- Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes.
- Lixisenatide: A New Option for Managing Type 2 Diabetes.
- Tirzepatide and the new era of twincretins for diabetes.
- The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
- Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
- Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies.
- Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
- Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
- Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
- A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol.
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.
- Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy.
- Effects of liraglutide on extraglycemic inflammatory markers and renal hemodynamic parameters in diabetic kidney disease (DKD).
- Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
- Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.
- Mitigation of Hearing Damage With Liraglutide Treatment in Chinchillas After Repeated Blast Exposures at Mild-TBI.
- A sensitive method for the quantitation of the peptide-based glucagon-like peptide-1 receptor agonist liraglutide in plasma using microfluidics chromatography tandem MS.
- Emerging Role of Semaglutide and GLP-1 Agonist Medications in Plastic Surgery: A Note of Caution.
- Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans.
- Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.
- Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations.
- Impact of a pharmacist-led weight management service in a cardiology clinic.
- Exenatide promotes cardiac lncRNAs HOX transcript antisense RNA (HOTAIR) in Wistar rats with liver cirrhosis; a novel role of GLP-1 receptor agonists in cirrhotic cardiomyopathy.
- Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?
- Controlling the uncontrolled variation in the diet induced obese mouse by microbiomic characterization.
- Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration.
- Cardiovascular Outcomes of New Medications for Type 2 Diabetes.
- Treating bile acid diarrhoea with liraglutide.
- Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
- GLP-1R agonist therapy and vaccine response: Neglected implications.
- Tirzepatide: a new low for bodyweight and blood glucose.
- Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
- Involvement of Glucagon-Like Peptide-1 in the Regulation of Selective Excretion of Sodium or Chloride Ions by the Kidneys.
- Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis.
- Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
- Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.